© 2018

Cancer II

  • Michael J. Waring

Part of the Topics in Medicinal Chemistry book series (TMC, volume 28)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. M. Raymond V. Finlay, Richard A. Ward
    Pages 39-39
  3. Yingying Zuo, Zhengying Pan
    Pages 75-104
  4. Kenneth W. Duncan, John E. Campbell
    Pages 227-227
  5. Dorin Toader
    Pages 289-289
  6. Ute F. Röhrig, Vincent Zoete, Olivier Michielin
    Pages 371-371
  7. Ian Robert Hardcastle
    Pages 399-399
  8. John M. Hatcher, Nathanael S. Gray
    Pages 435-467
  9. Back Matter
    Pages 469-475

About this book


This book reviews recent breakthroughs in anti-cancer drug discovery.  Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates.  The volume is divided into chapters that each relate to a specific protein or protein class.  Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates.  A summary of clinical data and the future outlook for the field is also provided.  Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.


Antibody drug conjugates BCR-ABL Bruton's tyosine kinase Cancer drug research DNA damage response Epidermal growth factor receptor Epigentic modulators FGFR Kinases Vascular endothelial growth factor

Editors and affiliations

  • Michael J. Waring
    • 1
  1. 1.Northern Institute for Cancer Research, ChemistryNewcastle UniversityNewcastle upon TyneUK

Bibliographic information

Industry Sectors
Chemical Manufacturing